companies

Tilt Biotherapeutics

Founded 2013
Employees 15+
Primary contact
Tukholmankatu 8 B
Biomedicum 2B, (2nd floor)
00290 Helsinki
Finland
Links
https://tiltbio.com/
Diseases & Conditions
Sections
TILT Biotherapeutics is a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary oncolytic adenoviruses armed with molecules, including cytokines that can stimulate or suppress T cells. The company's patented TILT technology, which can be delivered locally and systemically, modifies the tumor microenvironment and eliminates its ability to suppress immune responses to cancer, thereby enhancing T-cell therapies such as checkpoint inhibitors and CAR T therapies. TILT's lead asset, TILT-123, is a 5/3 chimeric serotype adenovirus armed with two human cytokines: TNF alpha and IL-2. TILT-123 has demonstrated a 100% response rate in pre-clinical cancer models in vivo, and it is currently in Phase 1 clinical trials. In addition to Finland, the company has an office in Cambridge, Massachusetts.
Select partners: Merck KGaA, Pfizer Alliance, MSD, Biotheus, University of Pennsylvania.
Founded 2013
Employees 15+
Primary contact
Tukholmankatu 8 B
Biomedicum 2B, (2nd floor)
00290 Helsinki
Finland
Links
https://tiltbio.com/
Diseases & Conditions
Sections

Funding 💰

Total €42.8M
Last round 🔗 €22M
Other
February 7, 2023.
Select investors Lifeline Ventures, European Innovation Council, Business Finland, Tesi, Stephen Industries, ACME Investments

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • Science: TILT was founded on the unique discovery that oncolytic adenoviruses potently stimulate T-cell responses in humans. The company's lead programme was designed by leveraging insights gained by its scientific founders from studies in 290 patients using 10 different prototype oncolytic viruses. 🔗
  • Promising pipeline: Tilt has multiple best-in-class oncolytic viral therapies in its pipeline. The company's lead therapeutic asset, TILT-123, is a cytokine armed oncolytic adenovirus that is currently in Phase 1 clinical trials as monotherapy and in combination with tumor infiltrating lymphocytes (TIL) therapy in Europe. 🔗
  • Experienced founder: TILT's founder and CEO Akseli Hemminki is a biotech entrepreneur and cancer clinician who has personally treated almost 300 patients with ten different oncolytic viruses. He leads a team of experienced industry professionals who collectively have decades of experience in the research, development, and commercialization of cancer therapeutics.

Video ▶️

Quotes 💬

“
We invest in future category-leading companies with strong founders, and support them through their growth. We saw the potential in TILT's cancer immunotherapies early on and continue to build on that potential in Europe as well as the U.S market with this funding round.
— Timo Ahopelto, Founding Partner of Lifeline Ventures 🔗
“
Combining grants and equity is unique to the European Innovation Council. It bridges the funding gap for highly innovative companies, unlocks additional private investments and enables them to scale up in Europe.
— Hermann Hauser, member of the EIC Fund Board 🔗
Last update: May 23, 2023